The U.S. Food and Drug Administration has approved Sylvant (siltuximab) to treat multicentric Castleman’s disease. MCD is a rare disorder that causes an abnormal overgrowth of immune cells in lymph ...
Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis. After combing through 4 ...
Poster presentations highlight AI-driven CD histopathology grading technology; morbidity and financial burden of idiopathic multicentric CD (iMCD); severity of pediatric iMCD; and CD subtype ...
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare ...
Castleman's disease represents a spectrum of rare lymphoproliferative disorders that share common histopathological features yet exhibit diverse clinical presentations. Traditionally divided into ...
A newly identified subtype of Castleman disease will help diagnose and properly treat thousands of patients who have been caught between existing classification systems, marking the first major ...
Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder that manifests with a wide range of histologic and clinical features. It is classified clinically into unicentric (UCD) and ...
A newly identified subtype of Castleman disease will help diagnose and properly treat thousands of patients who have been caught between existing classification systems, marking the first major ...
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman’s disease (iMCD). This rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results